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Abstract
This study aimed to examine the progression of large joint involvement from early to established RA in terms of range 
of movement (ROM) and time to joint surgery, according to the presence of rheumatoid factor (RF). We used a historical 
longitudinal cohort of early RA patients. Patients were deemed RF negative if all repeated assessments were negative. The 
rate of progression from normal to any loss of range of movement (ROM) from years 3 to 14 were modelled using general-
ized estimating equations, for elbows, wrists, hips, knees and ankle, adjusting for confounders. Time to joint surgery was 
analysed using multivariable Cox models. A total of 1458 patients were included (66% female, mean age 55 years) and 74% 
were RF-positive. The prevalence of any loss of ROM, from year 3 through to 14 was highest in the wrist followed by ankle, 
knee, elbow and hip. Odds of loss of ROM increased over time in all joint regions assessed, at around 7–13% per year from 
year 3 to 14. Time to surgery was similar according to RF-status for the wrist and ankle, but RF-positive cases had a lower 
hazard of surgery at the elbow (HR 0.37, 0.15–0.90), hip (HR 0.69, 0.48–0.99) and after 10 years at the knee (HR 0.41, 
0.25–0.68). Large joints become progressively involved in RA, most frequently affecting the wrist followed by ankle, which 
is overlooked in composite disease activity indices. RF-negative and positive cases progressed similarly. Treat-to-target 
approaches should be followed irrespective of RF status.
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Introduction
Rheumatoid arthritis (RA) is classically described as a sym-
metric small joint polyarthritis with additional involvement 
of large joints [1]. Small joint involvement dominates the 
classification criteria [2] and scoring tools for disease activ-
ity such as the 28-joint disease activity score (DAS28) and 
the clinical disease activity index (CDAI), where only 8 out 
of 28 included joints are large [3]. Analysis of joint dis-
tribution in RA reveals distinct stable clusters with some 
phenotypes restricted to small joints, and others involving 
wrist and large joints [3]. Involvement of large joints is asso-
ciated with joint destruction and more severe disease [1, 3, 
4], with consequences on long-term physical function and 
quality of life.
The distribution and prevalence of large joint disease 
assessed by clinical criteria at fixed time points has been 
provided by data from inception cohorts of early RA [1, 
5, 6] and cross-sectional studies in established disease [3, 
7]. There is a paucity of information concerning the onset 
Rheumatology
INTERNATIONAL 
 * Patrick D. W. Kiely 
 patrick.kiely@nhs.net
1 Institute of Life Course and Medical Sciences, University 
of Liverpool, Liverpool, UK
2 Centre for Rheumatic Diseases, King’s College London, 
London, UK
3 Rheumatology Department, King’s College Hospital, 
London, UK
4 Center for Health Services and Clinical Research and Post 
Graduate Medicine, University of Hertfordshire, Hatfield, 
UK
5 Department of Rheumatology, St Georges University 
Hospitals NHS Foundation Trust, Blackshaw Road, London, 
UK
6 Institute for Medical and Biomedical Education, St George’s 
University of London, London, UK
 Rheumatology International
1 3
and time course of damage in large joints, such as shoulder, 
elbow, hip, knee and ankle, from early to established RA, or 
of the influence of rheumatoid factor (RF) status.
There is a historic perception, now contested, that seron-
egative patients, who do not have RF and anti-citrullinated 
peptide (ACPA) antibodies, follow a milder less destructive 
course than those with these antibodies [8, 9]. This is in part 
derived from the finding that positive RF is one of the best 
predictors of small joint erosions [4, 10]. This perception 
might promote a bias in seronegative patients to select less 
aggressive treatment, such as non-methotrexate (MTX) con-
ventional synthetic disease modifying anti-rheumatic drug 
therapy (csDMARD), monotherapy and less rigid adherence 
to treat to target (T2T) strategies. Evidence to justify this 
comes from the CARDERA trial, where outcomes in ACPA 
negative patients were the same in those treated with csD-
MARD monotherapy as in those receiving intensive combi-
nation csDMARD therapy and prednisolone [11].
The historic nature of the Ealy Rheumatoid Arthritis 
Study (ERAS) provides a unique opportunity to study RA 
in the context of less aggressive, non-T2T strategies, as was 
the norm at the time. We aimed to assess individual upper 
and lower limb large joint progression, specifically in terms 
of range of movement (ROM) and time to joint surgery, in 
all patients and according to RF status.
Methods
Study population
ERAS was a multi-centre inception cohort of newly diag-
nosed RA patients (< 2 years disease duration, csDMARD 
naive), which recruited from nine district general hospitals 
in England from 1985 to 2001 with yearly follow-up for up 
to 25 (median 10) years. Patient recruitment into ERAS was 
based on clinician diagnosis with 70% of patients fulfill-
ing the minimum 1987 American Rheumatism Association 
criteria [12] at baseline and 96% by last visit. Patients sub-
sequently reclassified as non-RA were excluded from the 
study. Ethical approval was obtained from East Hertfordshire 
local research ethics committee and all participants provided 
written informed consent.
Treatment profiles
Patients were treated according to contemporaneous prac-
tice in each of the ERAS centres, without specific proto-
cols, strategies or other external influences. All centres 
followed the 1992 good practice guidance [13]. First line 
treatment was csDMARD monotherapy with/without ster-
oids in > 90%, favouring sulphasalazine (SSZ) from 1986 
to 2001, with a gradual switch to MTX monotherapy such 
that SSZ and MTX were used in equal proportions as first 
csDMARD by the end of the recruitment period [14]. Com-
bination csDMARDS were generally only used for more 
severe RA and only a small proportion of patients received 
bDMARDs [14]. Median time from RA symptom onset to 
first csDMARD initiation was 8 months.
Clinical, laboratory, radiographic and surgical 
outcome measures
Information on demographic, clinical, treatment, laboratory 
and functional features was recorded at baseline, between 
3 and 6 months, at 12 months and then annually on stand-
ardized case report forms, as previously described [14, 15]. 
Disease activity score (DAS) was calculated according to 
the original three variable method [16].
Range of movement (ROM) of individual shoulder, 
elbow, wrist, hip, knee, ankle and hindfoot joints was col-
lected at 3, 5, 9 and 12–15 years, the latter assigned as 
14 years. ROM was not assessed at baseline (year 0) in this 
study. Loss of ROM was categorised as normal, < 25%, 
26–50%, 51–75%, > 75% reduction and 100% (ankylosis). 
Any loss of normal ROM was taken to indicate RA involve-
ment in the joint, and involvement of either left or right 
side was sufficient for that joint region to be designated as 
involved.
RF was measured in each recruiting centre by routine 
local laboratory technique, repeated at annual visits. ACPA 
was not available during the years of recruitment to ERAS. 
Patients were classified as RF-negative if all assessments for 
RF were negative, or as RF-positive if any RF result was at 
least weakly positive.
Radiographs of hands and feet were taken at years 0, 1, 2, 
3, 5, 7, 9 and scored according to the Larsen method [17]; 
scoring wrists, MCPs, PIPs and MTPs for ‘damage’ based 
on non-erosive joint space narrowing (range 0–50) and ‘ero-
sions’ (0, 1, 2). Radiographs of hands and feet were also 
assessed for osteoarthritis (OA) according to the Lawrence 
method [18]. Radiographs were not routinely taken of other 
large joints.
Surgical procedures at the shoulder, elbow, wrist, knee 
and ankles were obtained by linking to Hospital Episodes 
Statistics and the National Joint Registry as previously 
described [15]. Any operative intervention was included, 
such as arthroplasty, fusion and arthroscopic surgery.
Statistics
Descriptive statistics were used to compare patient and 
disease characteristics by RF status. The rate of progres-
sion from normal to any loss of ROM over time (years) was 
modelled using generalized estimating equations (GEE) with 
logit link. Models were adjusted for baseline RF-status, age, 
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gender, BMI; and the following time varying covariates: 
haemoglobin (g/dL), DAS, Health assessment Question-
naire (HAQ), erosions, and osteoarthritis (on radiographs 
of the hands or feet), each assessed at the same time point 
as ROM. Missing time-varying covariates were imputed 
using the last value carried forward. The odds ratios from 
this model indicate the annual percentage change in odds 
of losing normal ROM (i.e., transition from normal to any 
degree of ROM loss) from 3 to 14 years. An interaction term 
between RF-status and time was used to test the difference in 
annual change between RF-positive and negative groups. To 
facilitate interpretation, models were stratified by RF status 
to provide estimates for each group. Change in the Larsen 
wrist damage score was modelled using GEE as a continu-
ous variable, while the erosion score was dichotomised into 
present/absent, using the same covariates as above.
Time to surgery in the RF-positive and negative groups 
were compared using the Kaplan–Meier estimator and log-
rank test. Those with no follow-up time beyond baseline 
were assigned an arbitrarily small amount of time that did 
not change the overall patient-time. Cox models were used 
to derive hazard ratios (HR) adjusted for baseline age, gen-
der and smoking status. Variables violating the proportional 
hazards assumption (tested using Schoenfeld residuals) were 
stratified in the model (i.e., allowing strata specific baseline 
hazards). Where survival curves clearly cross, models were 
performed separately for the time before and after crossing. 
Censoring was defined by the last follow-up.
As sensitivity analysis, we additionally adjusted for dep-
rivation (index of multiple deprivation, IMD, 1 indicating 
most deprived and 5 least), smoking status (categorised as 
ever, never and missing), and the rheumatic disease comor-
bidity index (RDCI) [19].
Results
Baseline characteristics
A total of 1465 patients were enrolled of whom 1458 
(> 99%) had RF data available, constituting the analysis 
population. RF was measured at baseline in all patients and 
repeated annually in 62–69% of cases from years 1 to 5 and 
in 37–56% of cases at each time point from years 6 to 10. 
Table 1 shows the baseline characteristics. 74% of patients 
were RF positive. RF-negative patients resided in more 
deprived areas, had a higher swollen joint count and HAQ, 
lower ESR and Hb and fewer were ever smokers or had ero-
sions (anywhere in hands and feet). There was no statisti-
cal difference between RF-positive and negative patients in 
gender (66 vs 68% females), baseline age (55 vs 57 years), 
BMI, DAS, pain VAS, co-morbidities (RDCI), Larsen wrist 
damage and erosion scores, and Lawrence OA status.
Range of movement in individual joints
The proportion of patients with any loss of ROM in either 
of shoulder, elbow, wrist, hip, knee, ankle and hind foot, 
measured at year 3, 5, 9 and 14, are shown in Fig. 1 and 
Supplementary Table S1. The wrist was the joint with the 
highest proportion of patients exhibiting any loss of ROM, 
affecting 43% at year 3 and rising sequentially to 71% at 
year 14. The proportion of patients with any loss of ROM 
of the elbow, hip, knee and ankle was less than half of 
those with wrist involvement at all time points, but also 
incrementally rising through to year 14. Supplementary 
Figure S1 shows the proportion of patients with differing 
degrees of loss of ROM per joint at each time point. The 
proportion of patients at year 9 with greater than 25% loss 
of ROM was as follows: wrist 30%, ankle 12%, elbow 7%, 
knee 7% and hip 5%.
At the first ROM assessment (year 3), RF-positive par-
ticipants had  significantly lower odds for any loss of ROM 
at the hip (OR 0.56; 95 CI 0.40, 0.77) and ankle (OR 0.58; 
95% CI 0.43, 0.79) compared to RF-negative, whereas 
there was no significant difference for other joints (online 
Supplementary Table S1). Modelling showed a statistically 
significant increase in odds of loss of ROM over time in all 
joint regions assessed, at around 7–13% per year from year 
3 to 14 (Fig. 2). Interaction terms and models stratified by 
RF-status showed no significant difference between RF-
positive and RF-negative patients (Fig. 2). Detailed model 
coefficients are shown in Supplementary Tables S2-4. Sen-
sitivity analyses additionally adjusting for smoking, RDCI 
and index of multiple deprivation (IMD) showed no mean-
ingful differences (Supplementary Figure S2).
Radiographic assessment of the wrist
RF-positive patients had significantly higher odds of hav-
ing any erosions at the wrist at year 0 (OR 1.58; 95% CI 
1.11, 2.25) versus RF-negatives. Over time (year 0–9), 
erosions developed (change in Larsen erosion score 
from 0 to ≥ 1) at the wrist in the entire population, with 
annual increase OR 1.26 (95% CI 1.22, 1.30). This rate 
of increase was statistically higher in RF-positives than 
RF-negatives (p for interaction term = 0.013); stratified 
annual odds of developing any erosions for RF-positive 
participants was OR 1.28 (95% CI 1.24, 1.32) and for RF-
negatives OR 1.17 (95% CI 1.09, 1.26) (full model coeffi-
cients in Supplementary Table S5). Larsen damage scores 
also progressed in all patients (Fig. 3), with linear mixed 
models revealing a faster rate of progression in the RF-




Table 1  Baseline characteristics of patients included for analysis
DAS disease activity score, Hb haemoglobin, HAQ health assessment questionnaire, IMD index of multiple deprivation; RDCI rheumatic disease 
comorbidity index, VAS visual analogue scale; (n= participants with available data)
a Patients were classified as RF-negative if all assessments were negative, or as RF-positive if any RF result was at least weakly positive
b By Lawrence score
All patients RF-negative RF-positivea p value
No. of participants 1465 377 1081
Age at baseline visit, mean (SD) 55.4 (14.6) 56.6 (15.4) 55.0 (14.3) 0.065
Female 973 (66%) 255 (68%) 715 (66%) 0.60
Ever smoker 388 (42%) (n = 915) 72 (35%) (n = 204) 316 (44%) (n = 711) 0.020
IMD
 1, most deprived 208 (15%) 85 (24%) 123 (12%) < 0.001
 2 228 (17%) 73 (20%) 155 (15%)
 3 278 (20%) 58 (16%) 220 (22%)
 4 280 (20%) 71 (20%) 209 (21%)
 5, least deprived 381 (28%) 74 (20%) 307 (30%)
BMI, mean (SD) 25.6 (4.5) (n = 1267) 26.0 (4.7) (n = 310) 25.4 (4.4) (n = 957) 0.074
HAQ, mean (SD) 1.1 (0.8) (n = 1453) 1.3 (0.8) (n = 375) 1.1 (0.8) (n = 1078) < 0.001
DAS, mean (SD) 4.8 (1.3) (n = 1446) 4.8 (1.2) (n = 375) 4.7 (1.3) (n = 1071) 0.61
ESR, median (IQR) 37.0 (18.0, 62.0) (n = 1451) 35.0 (16.0, 57.0) (n = 375) 38.0 (19.0, 64.0) (n = 1076) 0.036
Hb, mean (SD) 12.6 (1.6) (n = 1453) 12.4 (1.5) (n = 376) 12.7 (1.6) (n = 1077) 0.003
Pain VAS, mean (SD) 44.0 (26.4) (n = 1405) 43.5 (26.9) (n = 356) 44.1 (26.2) (n = 1049) 0.71
Swollen joint count, ‘44’ version, 
median (IQR)
15.0 (7.0, 26.0) (n = 1455) 18.0 (9.0, 28.0) (n = 377) 14.0 (7.0, 25.0) (n = 1078) < 0.001
RDCI, mean (SD) 0.3 (0.6) (n = 1458) 0.3 (0.6) (n = 377) 0.3 (0.6) (n = 1081) 0.51
Baseline erosions 1084 (75%) 215 (57%) 869 (81%) < 0.001
Larsen Wrist damage, mean (SD) 1.3 (5.0) (n = 1159) 1.0 (3.7) (n = 278) 1.4 (5.3) (n = 881) 0.15
Wrist erosion (Larsen score > 0) 70 (6%) 14 (5%) 56 (6%) 0.58
Hands  OAb 152 (11%) 34 (10%) 118 (12%) 0.37
Feet  OAb 204 (16%) 56 (18%) 148 (15%) 0.30
Hands joint space  narrowingb 60 (4%) 14 (4%) 46 (5%) 0.71
Feet joint space  narrowingb 37 (3%) 6 (2%) 31 (3%) 0.23
Fig. 1  Proportion of partici-
pants with any loss of range of 





The overall percentage of patients undergoing joint sur-
gery at any site was low over 25 years’ maximum follow-
up. Kaplan Meier estimates for the hip and knee are shown 
in Fig. 4 (other joints shown in Supplementary Figure S3). 
RF-positive patients had lower hazard of surgery at the 
elbow (HR 0.37; 95% CI 0.15, 0.90) and hip (HR 0.69; 95% 
CI 0.48, 0.99). For knee surgery the proportional hazards 
assumption was violated (curves crossed at 10 years). Cox 
models of years 0 to 10 showed no significant difference 
in hazard of knee surgery (HR 1.45; 95% CI 0.80, 2.63), 
whereas from year 10 onwards the hazard was HR 0.41 lower 
in the RF-positive participants (95% CI 0.25, 0.68). There 
was no significant difference in rate of surgery between RF-
positive and RF-negative patients at the shoulder (HR 1.35; 
0.39, 4.68), wrist (HR 0.91; 0.43, 1.92) and ankle (HR 0.86; 
0.30, 2.45) (full model coefficients shown in Supplementary 
Table S7).
Discussion
We present findings from ERAS, a historic inception cohort 
of newly diagnosed RA patients, recruited between 20 and 
35 years ago, followed for a median of 10 years. This was 
at a time when contemporary management was very differ-
ent to now; employing less intense follow-up, non-targeted 
treatment adjustments and less aggressive treatment choices 
usually not including MTX, and rarely combination csD-
MARD therapies. This provides the opportunity to study 
the natural history of this disease if under treated according 
to today’s standards.
We have focussed on large joint disease, which clusters 
separately from small joint disease [3], and has a strong 
influence on disability and quality of life [4, 7, 20, 21]. In 
ERAS we report an incremental involvement of all large 
joints assessed from year 3 to 14, using loss of normal 
Fig. 2  Odds of progression to any loss of ROM (from no loss of 
ROM) per year in the overall population and stratified by RF status. 
Models assumed linear progression from 3 to 14 years, adjusted for 
RF status (in the overall population only), age, gender, BMI, baseline 
and time-varying erosions, Hb, HAQ, DAS, OA hand and feet joint 
space narrowing. For example, odds of progression from no to any 
loss of ROM in the shoulder increased by 10% per year, and did not 
differ significantly between RF-groups




ROM as a measure of RA damage. This tool is a reliable 
and valid measure of large joint RA with clinical utility 
[22], is indicative of disability [20] and correlates with 
standard measures of damage [21]. The prevalence of wrist 
disease was by far the highest, rising from 43% at year 
3 to 71% of all patients at year 14; its predominance is 
in keeping with other cohorts [3–5, 7]. Prevalence of hip 
disease was the lowest, rising from 12% at year 3 to 24% 
at year 14, with elbow, knee and ankle much the same, ris-
ing to 26–33% of cases at year 14. There is a remarkable 
paucity of published information on the time course of 
joint involvement in RA; we believe our data from ERAS, 
showing the prevalence of disease, and similar odds of 
progression over time in all large joints is unique.
Fig. 4  Kaplan Meier estimates 




An important and perhaps surprising finding was that 
ankle involvement is as prevalent as other large joints, yet 
omitted from composite disease activity scores such as 
DAS28 and CDAI. Furthermore, by year 9 the ankle was 
the most prevalent large joint (after the wrist) to exhibit 
higher degrees of loss of ROM, nearly twice as prevalent 
as elbow and knee. A high prevalence of ankle disease 
in established RA has also been reported in other series, 
including 735 patients with established active RA used to 
develop the DAS28 score, where ankle involvement based 
on joint swelling was even higher than in ERAS, recorded in 
62% compared to knee 52% and elbow 37% [3]. In another 
cohort of 997 patients with established RA, asked to self-
report joint involvement, the prevalence of hindfoot/ankle 
disease was 17%, knee 32% and elbow 14%; and in early RA 
cohorts from four countries, prevalence of ankle involvement 
assessed by joint swelling ranged from 20 to 45% [5]. In an 
early RA cohort, elbow and ankle prevalence were both 14% 
and knee 25% in the sub-group with the most destructive 
disease at 1 year [4], not dissimilar to the ERAS prevalence 
at year 3 (16%). We highlight that ankle disease is prevalent 
in established RA, and potentially over looked if the foot is 
not examined, as might occur if assessment is restricted to 
the 28 joint count included in the DAS28 and CDAI scores. 
Indeed, we have reported previously that only one-third of 
this cohort accessed podiatry [23].
Data for RF were available for the ERAS cohort, but 
not ACPA as the study pre-dates its routine assessment in 
clinical practice. At baseline, we found a high prevalence 
of erosions on radiographs of wrists, MCP, PIP and MTP 
joints, involving 75% of the entire cohort, in keeping with 
other early RA cohorts [24]. Erosions were significantly less 
prevalent in those negative for RF (57%) compared to RF-
positive (81%); also found by others [10, 24]. This might 
be expected from the finding that, in ERAS, there were sig-
nificantly fewer ever smokers at baseline in the RF-negative 
versus RF-positive patients (35 vs 44%), a risk factor known 
to associate with erosive disease [25]. However, in contrast, 
other baseline poor prognostic attributes were more preva-
lent in RF-negative patients including a higher swollen joint 
count and HAQ and a higher proportion living in the most 
deprived areas. Despite the opposing influences of these 
prognostic factors, the findings in the ERAS cohort at base-
line are in keeping with others, that rheumatoid destruction 
of the wrist and small joints is more prevalent in RF-positive 
patients. Similarly, the ERAS data demonstrates a signifi-
cantly greater rate of progression of x-ray assessed damage 
and erosions at the wrist in RF-positive patients over time.
In large joints we found no significant difference in rate 
of loss of ROM over time between RF positive and negative 
cases. At year 3 we found RF-negative patients were more 
likely to have any loss of ROM at the hip and ankle than 
RF-positive patients, suggesting a more aggressive disease 
course at this stage. This is reflected in surgical outcomes, 
where RF-negative patients were found to have more pro-
cedures at the elbow and hip, and after 10 years at knee. 
This might be explained by a more aggressive pathology at 
these sites in RF-negative RA, as described in case reports 
[26]. Alternatively, mis-diagnosis might have influenced 
these outcomes, though in ERAS, patients were excluded if 
they later developed spondyloarthropathy or psoriatic arthri-
tis. Furthermore, in a series of 9784 cases of seronegative 
RA in Finland, the diagnosis was subsequently changed to 
peripheral spondyloarthropathy in only 10% of patients over 
15 years [27]. Osteoarthritis is known to co-exist with RA, 
but adjustment of the models for Lawrence assessed OA of 
hand and feet radiographs did not influence these results. We 
cannot exclude a faster time course to secondary OA in large 
joints of RF-negative versus positive patients. A systematic 
review of predictors of orthopaedic intervention in RA found 
no consistent influence of RF [28]. Taking these various fac-
tors into consideration, we conclude that RF-negative RA is 
at least as aggressive as RF-positive RA with respect to large 
joint involvement over time and our surgical data suggest 
that it may have a more destructive course, though absolute 
numbers of surgical interventions were low, making this a 
tentative observation.
The strengths of this study come from its real-world 
inception cohort design, with data collected from individual 
joints up to 14 years. Follow-up across all centres was rela-
tively high given the long-term nature of this prospective 
study. Of those not followed to death or closure, cases lost 
to follow-up for no known reason were only 12.5%, and full 
reasons have been previously reported [29]. Whilst treatment 
strategies differ from now, our findings provide an insight 
into the potential disease course in large joints when treated 
less aggressively and provide evidence against perceptions 
that RF-negative RA is a less aggressive form of this disease. 
We would, therefore, conclude that T2T strategies employ-
ing escalating doses of MTX and combination csDMARDs 
should be used as much for RF-negative as RF-positive 
disease.
A weakness of the study is the absence of ACPA or 
anti-carbamylated protein antibody data, neither being 
routinely available through the time course of ERAS. 
Interestingly, quantitative high-resolution CT findings of 
the metacarpal head demonstrate that the association of 
ACPA with erosions is principally seen in RF-positive 
patients, whereas significantly fewer erosions were found 
in RF-negative cases irrespective of ACPA status [30]. 
Similarly, in an inception cohort followed for 6 years, 
IgM RF had the strongest predictive influence on progres-
sion of function (HAQ) and small joint radiologic dam-
age whereas ACPA was only weakly predictive of damage 
[31]. Whether these findings also apply to large joints is 
unknown; the current study did not capture radiographic 
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progression in large joints other than the wrist. The use 
of loss of any ROM as a reliable and valid marker of RA 
joint involvement [20–22] has potential limitations, as 
non-RA processes might incur false positive conclusions. 
This is particularly the case for the shoulder where rotator 
cuff disease is prevalent, and we, therefore, do not wish 
to over interpret the shoulder-specific data. This study 
did not assess ROM at baseline which could have shed 
light on progression over the first three years after diag-
nosis. We have previously reported in a subgroup of this 
cohort that patients homozygous for the HLA DR4 shared 
epitope (SE) are more likely to have orthopaedic surgery, 
although the association was not strong [32], consistent 
with the known relationship of the SE with severity of RA, 
in addition to susceptibility. In the current study, the SE 
was related to greater loss of ROM at 9 years, reflecting 
overall severity of RA, but there were only minor differ-
ences between individual large joint ROM loss and the 
SE. Patients with mainly large joint involvement were less 
likely to exhibit the SE, compared to patients with mainly 
polyarticular or small joint arthropathy (data not shown).
In summary, this is a unique report of the course of 
involvement of large joints from early to established RA, 
demonstrating the natural history of disease when under-
treated by today’s standards. We highlight the prevalent 
involvement of the ankle, an under-mentioned and under-
examined joint in RA, excluded from composite scores such 
as DAS28. We have confirmed others in demonstrating a 
higher burden of erosions and damage at the wrists in RF-
positive patients, but not found RF-negative patients to have 
a better prognosis over time with respect to involvement of 
other large joints. In contrast, we present data to suggest that 
patients who are RF-negative have more joint surgery at the 
elbow, hip and knee after 10 years. There is no justification 
to adopt a less aggressive treatment strategy for RF-negative 
RA. High vigilance and treat-to-target approaches should be 
followed irrespective of RF status.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00296- 021- 04931-2.
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